<html>
<head>PUBMED IDs for GRIT</head>
<body bgcolor='#C5F0F2'><h1>GRIT</h1><a href='https://pubmed.ncbi.nlm.nih.gov/19808198/'>MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.</a> May 19  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/21703979/'>Bezafibrate, a lipid-lowering pharmaceutical, as a potential endocrine disruptor in male zebrafish (Danio rerio).</a> November 11  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/26659915/'>Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.</a> January 5  2015<br><a href='https://pubmed.ncbi.nlm.nih.gov/26768687/'>Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.</a> January 10  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27132212/'>Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.</a> June 6  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/28377388/'>Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction.</a> April 6  2017<br></body></html>
